Non-Current Liabilities
Long-Term Debt
Bristol-Myers Squibb Long-Term Debt decreased by 1.6% to $42.15B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 8.7%, from $46.16B to $42.15B. Over 5 years (FY 2020 to FY 2025), Long-Term Debt shows a downward trend with a -2.4% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Liabilities
CategoryLeverage
SignalContext dependent
VolatilityStable
First reportedQ1 2014
Last reportedQ1 2026Apr 30, 2026
How to read this metric
High levels increase financial risk and interest expense, but can also indicate the company's ability to leverage its balance sheet for growth.
Detailed definition
This represents the total principal amount of debt obligations with maturities extending beyond one year. It is a key co...
Peer comparison
Pharmaceutical companies often carry significant long-term debt to fund large-scale acquisitions and clinical trial pipelines.
Metric ID:
long_term_debtHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $42.5B | $39.68B | $39.61B | $37.45B | $37.11B | $36.97B | $35.06B | $35.08B | $34.66B | $32.14B | $36.65B | $49.49B | $48.86B | $48.67B | $47.6B | $46.16B | $44.47B | $44.47B | $42.85B | $42.15B |
| QoQ Change | — | -6.6% | -0.2% | -5.4% | -0.9% | -0.4% | -5.2% | +0.1% | -1.2% | -7.3% | +14.1% | +35.0% | -1.3% | -0.4% | -2.2% | -3.0% | -3.7% | -0.0% | -3.6% | -1.6% |
| YoY Change | — | — | — | — | -12.7% | -6.8% | -11.5% | -6.3% | -6.6% | -13.1% | +4.6% | +41.1% | +41.0% | +51.5% | +29.9% | -6.7% | -9.0% | -8.6% | -10.0% | -8.7% |
Range$32.14B – $49.49B
CAGR-0.2%
Avg YoY Growth+4.2%
Median YoY Growth-6.8%
Current Streak8 quarters decline
Long-Term Debt at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's long-term debt?
- Bristol-Myers Squibb (BMY) reported long-term debt of $42.15B in Q1 2026.
- How has Bristol-Myers Squibb's long-term debt changed year-over-year?
- Bristol-Myers Squibb's long-term debt decreased by 8.7% year-over-year, from $46.16B to $42.15B.
- What is the long-term trend for Bristol-Myers Squibb's long-term debt?
- Over 5 years (2020 to 2025), Bristol-Myers Squibb's long-term debt has grown at a -2.4% compound annual growth rate (CAGR), from $48.34B to $42.85B.
- What does long-term debt mean?
- Total debt obligations that are not due for repayment within the next year.